Literature DB >> 6884401

Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency.

E Ott, H Lechner, F Fazekas.   

Abstract

The influence of pentoxifylline (11-18 mg/kg orally, Trental 400) on impaired hemorheologic conditions has been investigated in a total of 73 patients with CVI. Throughout a treatment period of 4 weeks, there was a significant improvement in red cell behavior and a significant inhibition of increased platelet aggregation; moreover, a fall in plasma fibrinogen and of blood viscosity has also been observed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6884401     DOI： 10.1159/000115658

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


  12 in total

Review 1.  Drugs affecting plasma fibrinogen levels.

Authors:  G di Minno; M Mancini
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

2.  Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.

Authors:  G Ciuffetti; M Mercuri; C Ott; R Lombardini; R Paltriccia; G Lupattelli; L Santambrogio; E Mannarino
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Effect of oxpentifylline on blood viscosity and cerebral blood flow in man.

Authors:  M M Brown
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

4.  24-h blood glucose pattern in type I and type II diabetics after oral treatment with pentoxifylline as assessed by artificial endocrine pancreas.

Authors:  S Raptis; A Mitrakou; D Hadjidakis; E Diamantopoulos; C Anastasiou; A Fountas; R Müller
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

Review 5.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

6.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 7.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

8.  Severe isolated thrombocytopenia after clopidogrel and pentoxifylline therapy: a case report.

Authors:  Elisa Celeste da Silva Vedes; Lia Dulce Guerreiro Marques; Miguel Cordovil Toscano Rico
Journal:  J Med Case Rep       Date:  2011-07-04

Review 9.  Pentoxifylline for vascular health: a brief review of the literature.

Authors:  Mark F McCarty; James H O'Keefe; James J DiNicolantonio
Journal:  Open Heart       Date:  2016-02-08

10.  Differential Effects of Pentoxifylline on Learning and Memory Impairment Induced by Hypoxic-ischemic Brain Injury in Rats.

Authors:  Hülya Halis; Soner Bitiktaş; Osman Baştuğ; Burak Tan; Şehrazat Kavraal; Tamer Güneş; Cem Süer
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.